Covidien PLC (COV)

COV (NYSE:Health Services)
$65.21
neg -0.04
-0.06%
Today's Range: 64.59 - 65.45 | COV Avg Daily Volume: 2,542,300
Last Update: 05/23/13 - 4:01 PM EDT
Volume: 2,327,235
YTD Performance: 13.01%
Open: $64.80
Previous Close: $65.25
52 Week Range: $50.25 - $68.83
Oustanding Shares: 470,474,681
Market Cap: 30,957,234,010
6-Month Chart
TheStreet Ratings Grade for COV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 13 13 14
Moderate Buy 1 1 1 1
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 1 1
Mean Rec. 1.28 1.28 1.50 1.47
Latest Dividend: 0.26
Latest Dividend Yield: 1.58%
Dividend Ex-Date: 04/02/13
Price Earnings Ratio: 17.05
Price Earnings Comparisons:
COV Sector Avg. S&P 500
17.05 17.10 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.92% 22.51% 57.88%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.40 0.11 0.04
Net Income 2.00 1.11 0.28
EPS 4.50 1.20 0.30
Earnings for COV:
EBITDA 3.14B
Revenue 11.85B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (09/13) FY (09/14)
Average Estimate $0.90 $0.92 $3.70 $4.06
Number of Analysts 7 7 12 10
High Estimate $0.93 $0.94 $3.73 $4.13
Low Estimate $0.88 $0.89 $3.67 $4.00
Prior Year $1.07 $1.02 $4.07 $3.70
Growth Rate (Year over Year) -16.02% -10.22% -9.17% 9.86%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
SeekingAlpha
SeekingAlpha: Best And Worst ETFs And Mutual Funds: Mid-Cap Value Style http://t.co/VFwjqEYqtA $COV $IVOV $JKI $MDYV $RFV $SATS $EZM $VOE $IJJ
14 hours ago from Seeking Alpha
BV_Healthcare
BV_Healthcare: $COV Covidien and Mallinckrodt to Present at Deutsche Bank Conference.. http://t.co/EG73fJcTCw
15 hours ago from BoardVote.com
janastasiow
janastasiow: RT @FierceMedDev: #Covidien #ablation device wows in Barrett's esophagus reversal -- http://t.co/c66GqYN8aP $COV
1 day ago from Twitter for iPhone
OswaldLifeSci
OswaldLifeSci: RT @FierceMedDev: #Covidien #ablation device wows in Barrett's esophagus reversal -- http://t.co/c66GqYN8aP $COV
1 day ago from HootSuite
FierceMedDev
FierceMedDev: #Covidien #ablation device wows in Barrett's esophagus reversal -- http://t.co/c66GqYN8aP $COV
1 day ago from TweetDeck
Benzinga
Benzinga: Covidien Says Trial Data for Endoscopic Ablation Therapy Shows Elimination of Precancerous Esophageal Tissue http://t.co/47vGa5vqw0 $COV
2 days ago from Tweet Button
Trader3X
Trader3X: $COV - Something of an iH&S.
2 days ago from web
TMFBreaking
TMFBreaking: New issues in US corporate bond markets topped $46B last week. $PBR $MRK $AXP $THC $COV http://t.co/9ibDuh5E5F
2 days ago from web
DDNotesMaker
DDNotesMaker: Check out $COV on http://t.co/xk4m8ev98o
3 days ago from DDNotesMakerPost
MarketCurrents
MarketCurrents: Covidien (COV -0.1%) says its Nellcor pulse oximetry portfolio has received FDA 501(k) clearance for m... http://t.co/vPRpFFJale $COV
3 days ago from Seeking Alpha

The Only Bubble I See

By

Jim Cramer

 | Mar 4, 2013 | 6:00 AM EST

Safety stocks aren’t every going to be crushed, but could certainly stumble.

Scrutinizing the Tyco Split

By

Meena Krishnamsetty

 | Sep 19, 2012 | 12:30 PM EDT

The move seems sure to unlock value, but you might want to hold off a bit for a solid entry point.

bullishCovidien numbers raised at Jefferies

Sep 14, 2012 | 8:19 AM EDT

Shares of COV now seen reaching $66, Jefferies said. Estimates also raised as COV stays ahead of the pack. Buy rating.

3 Stocks I Saw On TV, July 30

By

Dan Fitzpatrick

 | Jul 30, 2012 | 8:39 AM EDT

Dan Fitzpatrick examines three stocks viewed onFast Money. Today's stocks include Amgen, Gilead, and Celgene.

bullishCovidien target raised at Jefferies

Mar 14, 2012 | 8:17 AM EDT

Shares of COV now seen reaching $61, Jefferies said. New product story supports continued growth. Buy rating.

bearishCovidien downgraded at Goldman

Jan 12, 2012 | 7:28 AM EST

COV was downgraded to Neutral, Goldman Sachs said. Company is facing lower end-market demand.

bullishCovidien target upped at Goldman

Dec 16, 2011 | 7:51 AM EST

COV target was boosted to $53, Goldman Sachs said. Pharma spin-off should help unlock value. Buy rating.

Analyst Actions -- 9/9/2011

By

David Peltier

 | Sep 9, 2011 | 7:53 AM EDT

Here's a look at today's top research calls.

Columnist Conversation / Market Updates

Google Faces More Antitrst Probes
By

Doug Kass

 | May 23, 2013 | 4:00 PM EDT
Google faces new antitrust probe over display ad market

Market on Close Imbalance on the Sell Side
By

Doug Kass

 | May 23, 2013 | 3:47 PM EDT
There is about $550 million to sell on the close.
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.